The Bangladesh Association of Pharmaceutical Industries (BAPI) has accused the government of expanding the list of essential medicines and fixing their prices without consulting drug manufacturers. The allegation was raised on Saturday at a workshop titled “Bangladesh Pharma Industry: Present Challenges and Future Prospects,” jointly organized by BAPI and the Bangladesh Health Reporters Forum (BHRF) in Gazipur. BAPI leaders said the decision ignored production costs, international raw material prices, quality control, and market realities, posing long-term risks to medicine supply and industry stability.

BAPI Secretary General Dr. Md. Zakir Hossain criticized the policy process, saying no discussions were held with manufacturers or the association before the decision. He noted that the technical committee on pricing lacked members with real pharmaceutical experience. BAPI President Abdul Muktadir warned that about 60 percent of local drug companies are struggling, with nearly 40 percent already closed or near closure, threatening the country’s self-sufficiency in medicine. He urged government intervention to support small and medium firms and restore the industry’s health.

BAPI leaders also emphasized that Bangladesh’s pharmaceutical sector operates under strict regulatory oversight and called on journalists to highlight the challenges faced by struggling companies.